212 related articles for article (PubMed ID: 605911)
21. Results and further perspectives of plasmocytoma chemotherapy.
Sakalová A; Hrubisko M; Gazová S; Steruská M; Prümmerová J
Neoplasma; 1986; 33(2):251-8. PubMed ID: 3520353
[TBL] [Abstract][Full Text] [Related]
22. Therapy of multiple myeloma. Italian Multiple Myeloma Study Group.
Boccadoro M; Avvisati G; Cantonetti M; Cavo-Comotti BM; Frieri R; Gallamini A; Gallone G; Lauta VM; Liberati M; Marmont F
Pathol Biol (Paris); 1990 Oct; 38(8):829. PubMed ID: 2274374
[No Abstract] [Full Text] [Related]
23. Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis.
Gertz MA; Lacy MQ; Lust JA; Greipp PR; Witzig TE; Kyle RA
J Clin Oncol; 1999 Jan; 17(1):262-7. PubMed ID: 10458241
[TBL] [Abstract][Full Text] [Related]
24. Comparative chemotherapy of AKR lymphoma and human hematological neoplasia.
Frei E; Schabel FM; Goldin A
Cancer Res; 1974 Jan; 34(1):184-93. PubMed ID: 4520419
[No Abstract] [Full Text] [Related]
25. Multiple myeloma resistant to melphalan: treatment with cyclophosphamide, prednisone, and BCNU.
Kyle RA; Gailani S; Seligman BR; Blom J; McIntyre OR; Pajak TF; Holland JF
Cancer Treat Rep; 1979 Aug; 63(8):1265-9. PubMed ID: 476704
[TBL] [Abstract][Full Text] [Related]
26. [Therapy of multiple myeloma. Results of sequential treatment with melphalan-prednisolone and the M2 protocol].
Steinke B; Busch FW; Stapelfeld S; Ostendorf P; Waller HD
Dtsch Med Wochenschr; 1984 Jun; 109(26):1015-9. PubMed ID: 6547386
[TBL] [Abstract][Full Text] [Related]
27. Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experience.
Cornwell GG; Pajak TF; Kochwa S; McIntyre OR; Glowienka LP; Brunner K; Rafla S; Silver RT; Cooper MR; Henderson E; Kyle RA; Haurani FI; Cuttner J
Cancer; 1982 Nov; 50(9):1669-75. PubMed ID: 7116299
[TBL] [Abstract][Full Text] [Related]
28. Nitrosoureas in multiple myeloma.
Salmon SE
Cancer Treat Rep; 1976 Jun; 60(6):789-94. PubMed ID: 782701
[TBL] [Abstract][Full Text] [Related]
29. Combination chemotherapy for multiple myeloma.
Alexanian R; Bonnet J; Gehan E; Haut A; Hewlett J; Lane M; Monto R; Wilson H
Cancer; 1972 Aug; 30(2):382-9. PubMed ID: 5051662
[No Abstract] [Full Text] [Related]
30. Multiple myeloma resistant to melphalan: treatment with doxorubicin, cyclophosphamide, carmustine (BCNU), and prednisone.
Kyle RA; Pajak TF; Henderson ES; Nawabi IU; Brunner K; Henry PH; McIntyre OR; Holland JF
Cancer Treat Rep; 1982 Mar; 66(3):451-6. PubMed ID: 7060034
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of two-stage treatment of multiple myeloma with melphalan and with melphalan in combination with cyclophosphamide, carmustine, vincristine and prednisone.
Snigurowicz J; Kraj M; Rostkowska J; Maj S; Mariańska B; Mendek E; Roszkowski S; Kilian Z; Kołakowski L
Arch Immunol Ther Exp (Warsz); 1981; 29(2):145-53. PubMed ID: 7030265
[No Abstract] [Full Text] [Related]
32. [Chemotherapy of multiple bone myeloma. Historical and present day aspects. (Second part) (author's transl)].
Bataille R; Morlock G; Rosenberg F; Sany J; Serre H
Sem Hop; 1979 Sep 18-25; 55(31-32):1377-82. PubMed ID: 228415
[TBL] [Abstract][Full Text] [Related]
33. Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma.
Abramson N; Lurie P; Mietlowski WL; Schilling A; Bennett JM; Horton J
Cancer Treat Rep; 1982 Jun; 66(6):1273-7. PubMed ID: 7044535
[TBL] [Abstract][Full Text] [Related]
34. Treatment of plasma cell myeloma with cytotoxic agents.
Bergsagel DE; Pruzanski W
Arch Intern Med; 1975 Jan; 135(1):172-6. PubMed ID: 803363
[TBL] [Abstract][Full Text] [Related]
35. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of the M-2 protocol in previously untreated patients with advanced multiple myeloma.
Gössinger H; Bettelheim P; Neumann E; Hinterberger W; Korninger K; Niessner H; Pabinger-Fasching I; Bauer K; Lechner K
Blut; 1984 Nov; 49(5):383-8. PubMed ID: 6548652
[TBL] [Abstract][Full Text] [Related]
37. [Prognosis in myelomatosis treated with prednisone and cytostatics].
Hansen OP; Jessen B; Videbaek A
Ugeskr Laeger; 1973 Jun; 135(23):1169-73. PubMed ID: 4757116
[No Abstract] [Full Text] [Related]
38. [Survival and therapy of multiple myeloma. Apropos of 56 observed cases].
Locatelli F; Giovanelli E; Neretto G; Furno F; Pellerito R
Minerva Med; 1979 Mar; 70(13):925-33. PubMed ID: 220567
[TBL] [Abstract][Full Text] [Related]
39. Pseudohypercalcemia and hyperviscosity with neurological manifestations in multiple myeloma.
van Dijk JM; Sonnenblick M; Weissberg N; Rosin A
Isr J Med Sci; 1986 Feb; 22(2):143-4. PubMed ID: 3753959
[No Abstract] [Full Text] [Related]
40. Long-term survival of patients with multiple myeloma and acute renal failure at presentation.
Lazarus HM; Adelstein DJ; Herzig RH; Smith MC
Am J Kidney Dis; 1983 Mar; 2(5):521-5. PubMed ID: 6402926
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
